The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of thyroid gland disorder patients across the globe, preference to alternative treatment methods brings down the growth prospects of companies operating in the market. Nevertheless, with innovative marketing strategies and attempts at improving awareness among patients regarding the benefits of popular drugs could help companies strengthen their positions in the global thyroid gland disorders treatment market.
Some of the leading companies in the market are Merck KGaA, Takeda Pharmaceutical Company Limited, Pfizer, Inc., ALLERGAN, Novartis AG, AbbVie Inc., Sanofi S.A., Lannett Company, Inc., Aspen, and Mylan N.V.The global thyroid gland disorders treatment market had a valuation of US$1,954.7 mn in 2016 and is estimated to rise to a valuation of US$2,609.9 mn by 2025, expanding at a CAGR of 3.3% from 2017 to 2025.
Request A Sample-
Levothyroxine to Remain Most Popular Drug for Treating Hypothyroidism
On the basis of disorders, the global thyroid gland disorders treatment market has been categorized into hypothyroidism and hyperthyroidism. The hypothyroidism segment studies Levothyroxine and Liothyronine drug classes. Of these, the segment of Levothyroxine drug class accounted for nearly 94.6% share of the hypothyroidism treatment market in 2016 and is likely to remain dominant during the forecast period.